Jefferies analyst Biren Amin upgraded AveXis (AVXS) to Buy saying AVXS-101 data continues to improve. Yesterday's updated SMA Type 1 data continued to show no events in the therapeutic dose cohort and improving CHOP-INTEND score, Amin tells investors in a post-earnings research note. The analyst adds that he's received positive feedback from an expert who believes AVXS-101 and Biogen's (BIIB) and Ionis' (IONS) nusinersen should be complementary therapies while some patients may prefer to dose with AVXS-101 and then receive nusinersen if they deteriorate. Amin keeps a $42 price target for AveXis shares.